Expression of Tgfβ1 and Inflammatory Markers in the 6-hydroxydopamine Mouse Model of Parkinson's Disease

被引:41
|
作者
Haas, Stefan Jean-Pierre [1 ]
Zhou, Xiaolai [2 ,3 ]
Machado, Venissa [2 ,4 ,5 ]
Wree, Andreas [1 ]
Krieglstein, Kerstin [4 ]
Spittau, Bjoern [4 ]
机构
[1] Univ Rostock, Med Ctr, Inst Anat, D-18055 Rostock, Germany
[2] Univ Freiburg, Inst Anat & Cell Biol, Dept Mol Embryol, Hugstetter Str 55, D-79106 Freiburg, Germany
[3] Cornell Univ, Weill Inst Cell & Mol Biol, Dept Mol Biol & Genet, Ithaca, NY USA
[4] Univ Freiburg, Spemann Grad Sch Biol & Med SGBM, Hugstetter Str 55, D-79106 Freiburg, Germany
[5] Univ Freiburg, Fac Biol, Hugstetter Str 55, D-79106 Freiburg, Germany
来源
关键词
6-OHDA; microglia; astrocytes; Tnfu; Tgf beta 1; GROWTH-FACTOR BETA-1; MICROGLIAL ACTIVATION; TIME-COURSE; 6-OHDA; SYSTEM; CELLS; NEURONS; NG2; MACROPHAGES; ASTROCYTES;
D O I
10.3389/fnmol.2016.00007
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Parkinson's disease (PD) is a neurodegenerative disorder that is characterized by loss of midbrain dopaminergic (mDA) neurons in the substantia nigra (SN). Microgliamediated neuroinflammation has been described as a common hallmark of PD and is believed to further trigger the progression of neurodegenerative events. Injections of 6-hydroxydopamine (6-OHDA) are widely used to induce degeneration of mDA neurons in rodents as an attempt to mimic PD and to study neurodegeneration, neuroinflammation as well as potential therapeutic approaches. In the present study, we addressed microglia and astroglia reactivity in the SN and the caudatoputamen (CPu) after 6-0HDA injections into the medial forebrain bundle (MFB), and further analyzed the temporal and spatial expression patterns of pro-inflammatory and anti-inflammatory markers in this mouse model of PD. We provide evidence that activated microglia as well as neurons in the lesioned SN and CPu express Transforming growth factor beta 1 (Tgf beta 1), which overlaps with the downregulation of pro-inflammatory markers Tnfu, and iNos, and upregulation of anti-inflammatory markers Yrn /and Argl. Taken together, the data presented in this study suggest an important role for Tgf beta 1 as a lesion-associated factor that might be involved in regulating microglia activation states in the 6-OHDA mouse model of PD in order to prevent degeneration of uninjured neurons by microglia-mediated release of neurotoxic factors such as Info and nitric oxide (NO).
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Neuroprotective effects of nicotine in a 6-hydroxydopamine model of Parkinson's disease
    Minamino, Hideaki
    Yanagida, Takashi
    Kitamura, Yoshihisa
    Taniguchi, Takashi
    Shimohama, Shun
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2008, 106 : 227P - 227P
  • [22] Transcriptome sequencing in a 6-hydroxydopamine rat model of Parkinson's disease
    Li, Jia
    Sun, Yajuan
    Chen, Jiajun
    GENES & GENETIC SYSTEMS, 2019, 94 (02) : 61 - 69
  • [23] Neuroprotection by safinamide in the 6-hydroxydopamine (6-OHDA) model of Parkinson's disease
    Sadeghian, M.
    Roach, A.
    Smith, K. J.
    MOVEMENT DISORDERS, 2011, 26 : S286 - S286
  • [24] Exercise-Induced Neuroprotection in the 6-Hydroxydopamine Parkinson’s Disease Model
    Zeinab Rezaee
    Sayed Mohammad Marandi
    Hojjatallah Alaei
    Fahimeh Esfarjani
    Neurotoxicity Research, 2020, 38 : 850 - 858
  • [25] Thrombin preconditioning provides protection in a 6-hydroxydopamine Parkinson's disease model
    Cannon, JR
    Keep, RF
    Hua, Y
    Richardson, RJ
    Schallert, T
    Xi, GH
    NEUROSCIENCE LETTERS, 2005, 373 (03) : 189 - 194
  • [26] Characterization of the gastrointestinal dysfunction in the 6-hydroxydopamine rat model of Parkinson's disease
    Chai, X.
    Diwakarla, S.
    Pustovit, R.
    McQuade, R.
    Di Natale, M.
    Ermine, C.
    Parish, C.
    Finkelstein, D.
    Furness, J.
    MOVEMENT DISORDERS, 2019, 34 : S629 - S629
  • [27] GDNF reduces oxidative stress in a 6-hydroxydopamine model of Parkinson's disease
    Smith, Michael P.
    Cass, Wayne A.
    NEUROSCIENCE LETTERS, 2007, 412 (03) : 259 - 263
  • [28] Exercise-Induced Neuroprotection in the 6-Hydroxydopamine Parkinson's Disease Model
    Rezaee, Zeinab
    Marandi, Sayed Mohammad
    Alaei, Hojjatallah
    Esfarjani, Fahimeh
    NEUROTOXICITY RESEARCH, 2020, 38 (04) : 850 - 858
  • [29] Therapeutic potential of bromelain in 6-hydroxydopamine rat model of parkinson's disease
    Cicek, B.
    Gul, M.
    Taghizadehghalehjoughi, A.
    Okkay, U.
    Yildirim, S.
    Okkay, I. F.
    Ertugrul, M. S.
    Aydin, I. C.
    Bayram, C.
    Arslan, Y. K.
    Hacimuftuoglu, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2020, 40 : S438 - S439
  • [30] The effect of thrombin on a 6-hydroxydopamine model of Parkinson's disease depends on timing
    Cannon, Jason R.
    Hua, Ya
    Richardson, Rudy J.
    Xi, Guohua
    Keep, Richard F.
    Schallert, Timothy
    BEHAVIOURAL BRAIN RESEARCH, 2007, 183 (02) : 161 - 168